Clene Inc.
General ticker "CLNN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $41.5M (TTM average)
Clene Inc. follows the US Stock Market performance with the rate: 44.5%.
Estimated limits based on current volatility of 6.9%: low 4.81$, high 5.52$
Factors to consider:
- Total employees count: 85 (-1.2%) as of 2023
- Top business risk factors: Economic downturns and volatility, Product commercialization failure, Labor/talent shortage/retention, Manufacturing disruptions, Inflation impact
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.78$, 8.96$]
- 2025-12-31 to 2026-12-31 estimated range: [2.26$, 7.46$]
Financial Metrics affecting the CLNN estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -64.31 <= 0.04
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -32.40 <= 19.35
- Negative: negative Industry operating income (median)
- Positive: Investing cash flow per share per price, % of 19.05 > -0.62
Short-term CLNN quotes
Long-term CLNN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.65MM | $0.34MM |
| Operating Expenses | $41.19MM | $33.44MM |
| Operating Income | $-40.54MM | $-33.09MM |
| Non-Operating Income | $-8.96MM | $-6.31MM |
| Interest Expense | $4.56MM | $4.06MM |
| R&D Expense | $26.66MM | $20.06MM |
| Income(Loss) | $-49.50MM | $-39.40MM |
| Profit(Loss)* | $-49.50MM | $-39.40MM |
| Stockholders Equity | $13.39MM | $-8.86MM |
| Inventory | $0.04MM | $0.07MM |
| Assets | $52.34MM | $27.34MM |
| Operating Cash Flow | $-30.17MM | $-21.33MM |
| Capital expenditure | $0.33MM | $0.01MM |
| Investing Cash Flow | $-1.50MM | $6.32MM |
| Financing Cash Flow | $42.16MM | $-1.53MM |
| Earnings Per Share** | $-9.43 | $-5.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.